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Dystonias are heterogeneous hyperkinetic movement disorders characterized by involun-
tary muscle contractions which result in twisting and repetitive movements and abnormal
postures. Several causative genes have been identified, but their genetic bases still remain
elusive. Primary Torsion Dystonias (PTDs), in which dystonia is the only clinical sign, can
be inherited in a monogenic fashion, and many genes and loci have been identified for
autosomal dominant (DYT1/TOR1A; DYT6/THAP1; DYT4/TUBB4a; DYT7; DYT13; DYT21;
DYT23/CIZ1; DYT24/ANO3; DYT25/GNAL) and recessive (DYT2; DYT17) forms. However
most sporadic cases, especially those with late-onset, are likely multifactorial, with genetic
and environmental factors interplaying to reach a threshold of disease. At present, genetic
counseling of dystonia patients remains a difficult task. Recently non-motor clinical find-
ings in dystonias, new highlights in the pathophysiology of the disease, and the availability
of high-throughput genome-wide techniques are proving useful tools to better understand
the complexity of PTD genetics. We briefly review the genetic basis of the most common
forms of hereditary PTDs, and discuss relevant issues related to molecular diagnosis and
genetic counseling.
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INTRODUCTION
Dystonias are a heterogeneous group of hyperkinetic move-
ment disorders characterized by involuntary muscle contractions,
resulting in twisting and repetitive movements and abnormal
postures (Fahn, 1988). Although the diagnosis is mainly clinical
(Albanese and Lalli, 2012), the current classification is based on eti-
ology, distinguishing primary torsion dystonias (PTDs), dystonia-
plus syndromes, heredodegenerative disorders and secondary dys-
tonias (Bressman, 2004). With the exclusion of secondary forms
which are related to acquired causes, dystonic syndromes have a
genetic basis. Several genes and loci have been identified (named
with the conventional DYT symbol followed by progressive num-
bers – see Table 1), yet a genetic diagnosis remains elusive in the
majority of patients. This review will focus on PTDs, tackling
current achievements, and challenges in genetic diagnosis.
THE COBWEB OF PTDs
In PTDs, dystonia is the only clinical sign (apart of tremor),
without evidence of identifiable exogenous causes or neurode-
generation. PTDs represent the third most common movement
disorder after Parkinson’s disease (PD) and essential tremor, and
include about 75% of dystonia cases (Phukan et al., 2011). The
clinical spectrum is broad and there is often a strong relationship
between age at onset and clinical severity. In early-onset PTDs,
dystonia usually generalizes within 5–10 years while, in late-onset
forms, dystonia tends to remain focal or segmental (Ozelius and
Bressman, 2011). A substantial proportion of early-onset cases
(<26 years) have a monogenic basis with autosomal dominant
(AD) or, more rarely, recessive (AR) inheritance (Table 1). Con-
versely, late-onset PTDs are complex disorders in which genetic
and environmental risk factors variably interplay to determine
the phenotype (Defazio et al., 2007). Yet this paradigm does
not always hold true in atypical cases where blurred clinical
signs and overlapping phenotypes can make genetic diagnosis a
difficult task.
AUTOSOMAL DOMINANT PTD
DYT1-dystonia is the most common form of early-onset PTD,with
an estimated frequency of 1/9,000 in Ashkenazi Jewish popula-
tion and 1/160,000 worldwide (Bressman et al., 2000). A recurrent
3 bp deletion (delGAG) in theTOR1A (TorsinA) gene on chromo-
some 9q34.11 is found in nearly all mutated cases (Ozelius et al.,
1997). The delGAG results in a glutamic acid residue loss in the
C-terminus conserved region of TorsinA protein; mutant TorsinA
shows aberrant cellular localization and impaired interaction with
other proteins, resulting in stress-induced abnormalities, synap-
tic vesicle recycling defects, and altered development of neuronal
pathways (Granata and Warner, 2010).
This mutation is found in diverse ethnicities, either inherited
as a founder mutation or – de novo (Klein et al., 1998; Ozelius and
Bressman, 2011), and only two additional mutations of unclear
pathogenicity (p.R288Q and p.F205I) have been described in iso-
lated atypical cases (Zirn et al., 2008; Calakos et al., 2010). The
delGAG is inherited as an AD trait and only 20–30% of mutation
carriers develop the disease (incomplete penetrance); interestingly,
penetrance appears to be markedly lower (∼3%) in patients carry-
ing the p.D216H polymorphism (rs1801968), suggesting that this
variant could act as a genetic modifier of the delGAG mutation
(Kamm et al., 2008). In most cases DYT1-dystonia starts dur-
ing childhood in a limb, with generalization occurring within
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Table 1 | Molecular classification of “DYT” dystonia syndromes.
Disease (MIM) Gene Locus Phenotype Inheritance
PURE PRIMARYTORSION DYSTONIA
DYT1 (128100) TOR1A 9q34 Early-onset generalized limb onset dystonia AD
DYT2 (224500) – – Early-onset generalized dystonia with prominent cranio-cervical
involvement
AR
DYT4 (128101) TUBB4a 19p13.12–13 Whispering dysphonia AD
DYT6 (602629) THAP1 8p11.21 Generalized cervical and upper-limb-onset dystonia AD
DYT7 (602124)* – 18p Adult-onset cervical dystonia AD
DYT13 (607671) – 1p36.32–p36.13 Cervical and upper-limb dystonia AD
DYT17 (612406) – 20p11.2–q13.12 Segmental or generalized dystonia with prominent dysphonia AR
DYT21 (614588) – 2q14.3–q21.3 Adult-onset generalized or multifocal dystonia, often starting with
blepharospasm
AD
DYT23 (614860) CIZ1 9q34 Adult-onset cervical dystonia AD
DYT24 (615034) ANO3 11p14.2 Cranio-cervical dystonia with laryngeal and upper-limb involvement AD
DYT25 (615073) GNAL 18p11 Adult-onset cervical dystonia AD
PRIMARY DYSTONIA-PLUS SYNDROME
DYT5 (218230) GCH1 14q22.2 Dopa-responsive dystonia AD
THD (605407) TH 11p15.5 Dopa-responsive dystonia AR
DYT11 (159900) SGCE 7q21.3 Myoclonus-dystonia AD
DYT12 (128235) ATP1A3 19q13.2 Rapid-onset dystonia parkinsonism AD
DYT15 (607488) – 18p11 Myoclonus-dystonia AD
DYT16 (612067) PRKRA 2q31.2 Early-onset dystonia parkinsonism AR
PAROXYSMAL SYNDROME
DYT8 (118800) MR1 2q35 Paroxysmal non-kinesigenic dyskinesia (PNKD) AD
DYT9 (601042)/DYT18
(612126)
SLC2A1 1p34.2 Paroxysmal dyskinesias with episodic ataxia and
spasticity/paroxysmal exercise-induced dystonia (PED)
AD
DYT10 (128200) PRRT2 16p11.2 Paroxysmal kinesigenic dyskinesia (PKD) AD
DYT19 (611031) – 16q13–q22.1 Paroxysmal kinesigenic dyskinesia 2 (PKD2) AD
DYT20 (611147) – 2q31 Paroxysmal non-kinesigenic dyskinesia 2 (PNKD2) AD
HEREDODEGENERATIVE DYSTONIA SYNDROME
DYT3 (314250) TAF1 Xq13.1 Dystonia parkinsonism X-R
AD, autosomal dominant; AR autosomal recessive: X-R, X linked recessive. *DYT7 locus on chromosome 18p has been recently questioned (Winter et al., 2012).
a few years from onset, but usually sparing the cranial-cervical
region. More rarely, dystonia may remain segmental or purely
focal (Ozelius and Bressman, 2011). Overall, clinical manifesta-
tions can vary widely even within families, ranging from dystonic
storm to mild writer’s cramp (Opal et al., 2002; Edwards et al.,
2003).
DYT6-dystonia is also a pure AD PTD, with reduced penetrance
(60%) and variable expressivity (Saunders-Pullman et al., 2007).
DYT6-dystonia is characterized by juvenile onset and frequent
generalization but, in contrast to DYT1-dystonia, cranial-cervical,
and laryngeal areas are frequently involved as the starting site.
Nevertheless, onset in adult age or in a limb, and lack of general-
ization, have all been reported (LeDoux et al., 2012). Mutations
in the THAP1 (thanatos associated protein-1) gene on chromo-
some 8p21–p22 were initially identified in Amish–Mennonite
families (Fuchs et al., 2009). Subsequently, about 60 familial and
sporadic cases have been reported worldwide (Blanchard et al.,
2011). Despite its dominant inheritance, a homozygous mutation
in THAP1 has been described in a consanguineous family with
generalized dystonia (Schneider et al., 2011). Since almost each
case bears a unique mutation, molecular diagnosis requires direct
sequencing of the whole THAP1 coding region.
Recently, thanks to the advent of Whole Exome Sequenc-
ing (WES) technology, four new genes have been implicated as
causative of AD focal/segmental dystonia. In one large Australian
family with fully penetrant juvenile-adult-onset “whispering dys-
phonia,” occasional generalization and alcohol benefit (Wilcox
et al., 2011), the p.R2G mutation in the TUBB4a gene (DYT4,
encoding the isoform a of b-Tubulin) has been identified by
exome sequencing (Hersheson et al., 2012). Molecular screening
of 394 phenotypically similar patients identified a novel muta-
tion (p.A271T) in one case (Lohmann et al., 2013). Mutations in
CIZ1 (DYT23,CDKN1A-interacting zinc finger protein-1),ANO3
(DYT24, Anoctamin 3, encoding a calcium-gated chloride chan-
nel highly expressed in the striatum), and GNAL (DYT25, guanine
nucleotide-binding protein, alpha-activating activity polypeptide,
olfactory type), have been identified in families with juvenile-
adult-onset cervical or cranial-cervical dystonia and in a few
sporadic cases with similar phenotypes (Charlesworth et al., 2012;
Xiao et al., 2012; Fuchs et al., 2013). In particular,GNAL mutations
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were detected in additional 6 out of 39 families (15%), suggesting
they could represent a major cause of adult-onset cranial-cervical
dystonia PTD.
Other AD PTD loci have been described in isolated familial
cases. The DYT7 locus was mapped to chromosome 18p in a fam-
ily with cervical PTD (Leube et al., 1996), but its existence has
been recently questioned (Winter et al., 2012). The DYT13 locus
was mapped to chromosome 1p36 in an Italian family with juvenile
onset dystonia, prominent cranial-cervical and arm involvement,
and occasional generalization (Bentivoglio et al., 2004) while, in
another family with adult-onset generalized/multifocal dystonia,
often starting with blepharospasm, the DYT21 locus was mapped
to 2q14.3–q21.3 (Norgren et al., 2011). For both loci, the causative
gene is still missing.
AUTOSOMAL RECESSIVE PTD
Few families with AR PTD have been described to date. These
include DYT2, an early-onset PTD with limb involvement and
rapid generalization (Khan et al., 2003), and DYT17, a juvenile
segmental/generalized dystonia with severe dysphonia mapped to
chromosome 20p11.2–q13.12 in a Lebanese family (Chouery et al.,
2008). The causative genes for these Mendelian PTDs still have to
be identified and their detection represents a challenge to address
with innovative techniques such as WES.
SPORADIC LATE-ONSET PTD
Late-onset PTD is about 10 times more frequent than early-onset
PTD with an estimated prevalence of 30/100,000 worldwide [Epi-
demiological Study of Dystonia in Europe (ESDE) Collaborative
Group, 2000]. The disease usually begins in adulthood and shows
limited tendency to spread or generalize. The majority of late-
onset PTD are sporadic, yet a positive family history is present
in up to 25% of first-degree relatives, supporting the existence
of genetic factors that could influence PTD susceptibility (Defazio
et al., 2012). It is hypothesized that most cases have a multifactorial
basis, in which common susceptibility genes interplay with indi-
vidual genetic and environmental risk factors to reach a threshold
of disease (Defazio et al., 2007).
In order to show an association between specific genetic vari-
ants and focal dystonias, many case-control studies have been
performed, focusing on candidate genes such as those related to
dopaminergic transmission, brain plasticity, and genes causative of
Mendelian PTDs; overall, these studies have yielded contradictory
outcomes. The (CT/GT/GA)n polymorphism in the dopamine D5
receptor gene has been associated with adult-onset focal dysto-
nia in patients of European ancestry, but not in other cohorts.
Similarly, a functional polymorphism (p.V66M, rs6265) in the
brain-derived neurotrophic factor (BDNF) gene and variants in
theTHAP1 gene have been associated to PTD risk, but with incon-
sistent results. More extensive work has been performed onTOR1A
variants. The p.D216H SNP was reported as a risk factor in patients
with familial focal/segmental dystonia, but these results were not
replicated in other studies. Several SNPs from the 3′ untrans-
lated region of TOR1A have also been implicated in focal dystonia
as predisposing factors in some studies but protective in others.
These contradictory data are likely due to confounding factors
including the small number of SNPs tested, limited samples size,
clinical heterogeneity of PTDs and different ethnicity (Ozelius and
Bressman, 2011).
NEW APPROACHES TO IMPROVE KNOWLEDGE ON PTD
GENETICS
Although 15 years have passed from the discovery of the first PTD
gene (Ozelius et al., 1997), the identification of new dystonia genes
has progressed slowly. This relates to the scarcity of large families
with several affected members, the fragmentary knowledge about
the pathogenetic mechanisms of dystonias and the difficulty in
identifying clinically homogeneous families or groups of patients
for genetic studies. Recently, the identification of PTD endophe-
notypes, the characterization of interactions between dystonia-
related proteins and the advent of innovative techniques such as
WES and genome-wide association studies (GWAS), provide new
hope in clarifying aspects of PTD.
UNRAVELING PTD ENDOPHENOTYPES
A major limitation in assessing PTD families is that clinical inves-
tigation is usually restricted to the motor phenotype, although
non-motor features have also been detected (Stamelou et al.,2012).
Recently, several studies based on neuroimaging, neurophysiologi-
cal, and expression profiling approaches have reported subclinical
abnormalities (endophenotypes) in healthy DYT1/DYT6 muta-
tion carriers (Fiorio et al., 2007; Bradley et al., 2009; Walter
et al., 2010; Niethammer et al., 2011; Phukan et al., 2011). For
instance, magnetic resonance diffusion tensor imaging used in
conjunction with probabilistic tractography have demonstrated
an anatomical disruption of cerebellar outflow in all DYT1/DYT6
carriers regardless of the phenotype, while a second protec-
tive downstream alteration of thalamo-cortical projections was
found in non-manifesting carriers only (Argyelan et al., 2009).
FDG-PET studies have shown relative metabolic increases in pre-
supplementary motor area and parietal association regions in
DYT1/DYT6 patients and a different pattern of abnormalities in
non-manifesting carriers (Carbon et al., 2004). In Raclopride-PET
imaging studies, significant reductions in radioligand binding have
been detected in both DYT1 and DYT6 carriers,being greater in the
latter, suggesting an intriguing link between DYT6 and dopamine
function (Carbon et al., 2009).
Similar approaches have been employed to detect endophe-
notypes among healthy relatives of patients with focal dystonias,
whose genetic bases are largely unknown. For example, somatosen-
sory spatial and temporal discrimination thresholds (TDT) have
been found altered not only in focal dystonia patients (Sanger
et al., 2001; Scontrini et al., 2009; Tinazzi et al., 2012) but also
in some healthy family members. Interestingly in these subjects a
correlation has been reported between abnormal tactile TDT and a
bilateral increase in putaminal gray matter detected by Voxel Based
Morphometry (Bradley et al., 2009).
Moreover, these findings may shed light on pathophysiological
mechanisms underlying primary dystonias. It is now established
that PTDs, traditionally regarded as a mere basal ganglia disease
without structural abnormalities, might be considered a neurode-
velopmental circuit disorder, in which maladaptive plasticity in
the sensory-motor cortex (Quartarone et al., 2009) and impaired
inhibition at different levels of the central nervous system are
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necessary to produce an overt motor manifestation (Albanese and
Lalli, 2012). As it is now clear that non-motor features are part of
the pathophysiological “fingerprint” of dystonia, endophenotypes
could represent valuable tools for future research. In this light,
neurophysiology and neuroimaging may facilitate the identifica-
tion of clinically non-manifesting mutation carriers within PTD
families, or may allow the clustering of homogeneous groups for
genetic studies (Stamelou et al., 2012).
CUES FROM PTD PATHOGENESIS
The PTDs phenotypic variability suggests genetic heterogeneity.
However clinical overlaps, not only within early-onset PTDs but
also with the more common focal/segmental dystonias, suggest
that common pathogenic mechanisms may be involved. Indeed,
recent functional studies have demonstrated that THAP1 and
TOR1A interact in a common pathway.
TorsinA, a member of the AAA+ superfamily, is involved in
multiple cellular functions (vesicle fusion, membrane trafficking,
protein folding, and cytoskeletal dynamics) and has a protective
role by maintaining a homeostatic threshold against the endothe-
lial reticulum (ER) stress. When mutated, its buffering capacity is
greatly diminished, its ATPase activity reduced and its ER translo-
cation prevented (Granata and Warner, 2010). Thap1 is a nuclear
transcription factor that can regulate endothelial cell proliferation
(Cayrol et al., 2007) but its function in the brain is still unknown.
In vitro studies have shown that Thap1 physically interacts with
TOR1A and represses TorsinA expression by binding to theTOR1A
promoter; this interaction is abolished by pathogenic mutations,
leading to a decreased repression (Kaiser et al., 2010). However,
the role of Thap1 as a major genetic modifier in DYT1-dystonia
has been recently questioned (Palada et al., 2012). In line with this,
Thap1 is predicted to regulate several other gene targets, including
the TAF1 gene which is also implicated in DYT3 dystonia (Mazars
et al., 2010).
The identification of the novel dystonia genes are contributing
to shed light on the pathogenetic mechanisms of PTD. TUBB4a is
supposed to be involved in neuronal cytoskeletal defects (Hersh-
eson et al., 2012), while ANO3 and GNAL mutations point to
a key role for striatal neurons in the pathophysiology of dys-
tonia, either through abnormal neuronal excitability related to
the malfunctioning of chloride channels or through abnormali-
ties of dopamine and/or adenosine signal transduction pathways
(Charlesworth et al., 2012; Fuchs et al., 2013). However functional
studies are needed in order to assess their specific role in the patho-
physiology of dystonia and their potential interactions with other
PTD genes.
NOVEL HIGH-THROUGHPUT STRATEGIES FOR IDENTIFICATION OF
PTD-RELATED GENES
To date, the identification of PTD genes and genetic risk factors
has proven to be a hard task. Recently, however, the introduction
of novel high-throughput technologies (WES and GWAS) have
boosted these fields (Kumar et al., 2012).
Whole exome sequencing can identify novel disease-causative
genes by sequencing the entire human exome in a single experi-
ment, and has truly revolutioned gene identification in Mendelian
disorders. In the field of dystonias, the first result was seen in
Paroxysmal Kinesigenic Dyskinesia (PKD, DYT10 locus), a rare
AD episodic dystonic syndrome characterized by recurrent and
brief attacks of involuntary movements triggered by sudden vol-
untary movements. Overlapping phenotypes include Infantile
Convulsions and Paroxysmal Choreoathetosis (ICCA) and Benign
Familial Infantile Seizures syndrome (BFIS). PKD, ICCA, and
other related phenotypes had been mapped to distinct loci at
the pericentromeric region of chromosome 16 (Tomita et al.,
1999; Swoboda et al., 2000; Valente et al., 2000), but the causative
gene(s) had long been elusive. Using WES, several groups inde-
pendently identified mutations in the PRRT2 gene as the major
cause of PKD and ICCA syndrome (Chen et al., 2011; Wang et al.,
2011; Lee et al., 2012), demonstrating the inaccuracy of map-
ping data. After gene identification, mutations were also identified
in pure BFIS families (Ono et al., 2012), as well as in occa-
sional cases with hemiplegic migraine (Dale et al., 2012). This
confirmed that mutations in the same gene can cause hetero-
geneous phenotypes, suggesting a genetic complexity previously
unexpected for Mendelian disorders (Schmidt et al., 2012). Sub-
sequently, the same WES approach has been successfully used to
identify four novel genes causative of late-onset PTD, as previously
described.
Genome-wide association studies, on the other hand, aim at
identifying polymorphic variants acting as risk factors for com-
plex diseases via large-scale, population-based studies. Thousands
of common variants (minor allele frequency >5%) can be simul-
taneously genotyped in large cohorts of patients and controls,
followed by a stringent statistical analysis to discriminate real hits
from false positive results. In movement disorders, this approach
has been largely adapted to PD, although the number of signif-
icant hits has been unexpectedly low and only few genes, such
as SNCA, MAPT, and LRRK2, have been found to harbor vari-
ants robustly associated with the disease. A recent meta-analysis
of GWAS studies in PD identified 17 additional disease risk loci
which surpassed the threshold for genome-wide significance, all
with low odds ratios (Kumar et al., 2012). To date there are no
published GWAS for PTDs, but their potential contribution to
the field is so obvious that many such projects are currently in
progress. It is expected that the new insights on PTD endophe-
notypes and the possibility to integrate worldwide data with a
meta-analytic approach, are going to shrink some of the confound-
ing factors that could have compromised previous association
studies.
MERGING PAST AND FUTURE: GENETIC AND COUNSELING
IN PTDs
Diagnosis of dystonia is mainly clinical, yet genetic analysis and
counseling is being requested more and more often. In primary
dystonias, genetic testing is only available for those forms of early-
onset PTD for which the gene is known (Figure 1). Testing of
the DYT1-delGAG, that is readily available and relatively inexpen-
sive, should be recommended for any PTD case with onset before
26 years and in those with later onset who have an affected relative
with early-onset dystonia. Other TOR1A mutations are extremely
rare and whole gene sequencing is not recommended in clinical
practice (Albanese et al., 2011). Sequencing of the other known
PTD genes (THAP1, TUBB4a, CIZ1, ANO3, and GNAL) should
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FIGURE 1 | Proposed flowchart for genetic testing in primary dystonias. GWAS, genome-wide association studies; WES, whole exome sequencing; mut,
mutation.
be considered in patients with predominant cranial-cervical and
laryngeal involvement, especially if family history is positive, with
prioritization according to the age at onset and distribution of
dystonia.
The identification of mutations in a proband requires a detailed
assessment of family history, given their dominant inheritance and
variable expression. Once a mutation is identified in a proband,
carrier testing is available for at-risk asymptomatic relatives who
may request it. This type of testing should never be performed
on minors and should always be accompanied by pre-test genetic
counseling. Since most PTD mutations show reduced penetrance,
it is impossible to predict whether a mutation carrier will develop
the disease, although such probability will progressively decrease
with age, especially for early-onset conditions such as DYT1
and DYT6. Yet, in case of positive testing, they need to under-
stand the 50% risk to transmit the mutation to their offspring
who could eventually develop the disease, based on estimated
penetrance.
Genetic diagnosis in sporadic late-onset PTD is much more
complex as several genetic and environmental factors are likely to
be involved. GWAS are significantly improving our understanding
of the complexity of sporadic PTDs, allowing the identification of
genetic susceptibility or protective factors for the development of
the disease. Yet, to avoid false expectation from commercially avail-
able genetic profiles, it should be remembered that such genetic
factors are relevant only in large population studies, while they
are of limited significance in personalized medicine (Kumar et al.,
2012).
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